Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Next Previous
Trial Profile

Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
  • Indications Acral lentiginous melanoma; Malignant melanoma; Skin cancer; Uveal melanoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Oct 2023 Pooled analysis result of NCT02231775 and NCT02519322 trial assessing relapse free survival at 3 years by pathological response to neoadjuvant systemic treatment in patients with surgically resectable, high-risk melanoma (n=97) presented at the 48th European Society for Medical Oncology Congress.
    • 06 Feb 2023 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2022 Primary endpoint (pathologic complete response (pCR) rate2) has been met, according to Results published in the Nature.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top